Table S1. Treatment details for the patients with metastatic NSCLC according to the line of treatment (n=56).

Type to treatment	N
Targeted therapy	38
Erlotinib	19
First-line	10a
Second-line	6
Third- line	2
Other line	1
Gefitinib	18
First-line	14
Second-line	4
Other line	0
Afatinib	9
First-line	3
Second-line	2
Third-line	3
Fourth-line	1
Other line	0
Chemotherapy	40
First-line	24
Second-line	24
Third-line	16
Fourth-line	10
Other line	7
None	5b

^aincluding one patient with L858R co-mutation; ^bincluding two patients with p.Leu858Arg co-mutation.